Cullinan Therapeutics shared new study results for velinotamig, showing four patients with lupus had complete kidney recovery.

Nov 8, 2026, 9:04 PM ETTrialRead the original at globenewswire.com

Good for CGEM

Four complete kidney responses in an ongoing early-stage lupus study are encouraging for Cullinan's drug program. The study is still underway, so these results do not yet show how well the treatment works overall.

CGEM · Cullinan Therapeutics, Inc.

AI read · Good for CGEM

The AI's read

The kidney responses give Cullinan an early sign that velinotamig may help people with severe lupus. The trial is still in Phase 1b/2a, so these results do not show how often patients respond or how well the drug works overall.

Get alerts for CGEM

Follow Cullinan Therapeutics, Inc. (CGEM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CGEM

Free on the App Store and Google Play, or on the web.